

Calcium Intake and Risk of Colorectal Cancer According to Tumor-infiltrating T Cells

Wanshui Yang^{1,2}, Li Liu^{3,4,5}, NaNa Keum^{4,6}, Zhi Rong Qian³, Jonathan A. Nowak^{7,8}, Tsuyoshi Hamada³, Mingyang Song^{4,9,10}, Yin Cao^{4,9,10,11}, Katsuhiko Noshō³, Stephanie A. Smith-Warner^{2,4}, Sui Zhang⁸, Yohei Masugi³, Kimmie Ng⁸, Keisuke Kosumi³, Yanan Ma^{12,13}, Wendy S. Garrett¹⁴, Molin Wang¹⁵, Hongmei Nan^{16,17}, Marios Giannakis^{7,18}, Jeffrey A. Meyerhardt⁷, Andrew T. Chan^{2,9,10,18}, Charles S. Fuchs^{19,20,21}, Reiko Nishihara^{3,4,5,8,15,18}, Kana Wu⁴, Edward L. Giovannucci^{4,5}, Shuji Ogino^{3,5,8,18}, and Xuehong Zhang²



Abstract

Calcium intake has been associated with a lower risk of colorectal cancer. Calcium signaling may enhance T-cell proliferation and differentiation, and contribute to T-cell-mediated antitumor immunity. In this prospective cohort study, we investigated the association between calcium intake and colorectal cancer risk according to tumor immunity status to provide additional insights into the role of calcium in colorectal carcinogenesis. The densities of tumor-infiltrating T-cell subsets [$CD3^+$, $CD8^+$, $CD45RO$ ($PTPRC$)⁺, or $FOXP3^+$ cell] were assessed using IHC and computer-assisted image analysis in 736 cancer cases that developed among 136,249 individuals in two cohorts. HRs and 95% confidence intervals (CI) were calculated using Cox proportional hazards regression. Total calcium intake was associated with a multivariable HR of 0.55 (comparing $\geq 1,200$ vs. < 600 mg/day; 95% CI,

0.36–0.84; $P_{\text{trend}} = 0.002$) for $CD8^+$ T-cell–low but not for $CD8^+$ T-cell–high tumors (HR = 1.02; 95% CI, 0.67–1.55; $P_{\text{trend}} = 0.47$). Similarly, the corresponding HRs (95% CIs) for calcium for low versus high T-cell-infiltrated tumors were 0.63 (0.42–0.94; $P_{\text{trend}} = 0.01$) and 0.89 (0.58–1.35; $P_{\text{trend}} = 0.20$) for $CD3^+$; 0.58 (0.39–0.87; $P_{\text{trend}} = 0.006$) and 1.04 (0.69–1.58; $P_{\text{trend}} = 0.54$) for $CD45RO^+$; and 0.56 (0.36–0.85; $P_{\text{trend}} = 0.006$) and 1.10 (0.72–1.67; $P_{\text{trend}} = 0.47$) for $FOXP3^+$, although the differences by subtypes defined by T-cell density were not statistically significant. These potential differential associations generally appeared consistent regardless of sex, source of calcium intake, tumor location, and tumor microsatellite instability status. Our findings suggest a possible role of calcium in cancer immunoprevention via modulation of T-cell function.

¹Department of Nutrition, School of Public Health, Anhui Medical University, Hefei, Anhui, P.R. China. ²Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts. ³Department of Oncologic Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts. ⁴Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts. ⁵Department of Epidemiology and Biostatistics, and the Ministry of Education Key Lab of Environment and Health, School of Public Health, Huazhong University of Science and Technology, Wuhan, P.R. China. ⁶Department of Food Science and Biotechnology, Dongguk University, Goyang, South Korea. ⁷Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts. ⁸Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. ⁹Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. ¹⁰Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. ¹¹Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St Louis, Missouri. ¹²Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. ¹³Department of Biostatistics and Epidemiology, School of Public Health, China Medical University, Shenyang, Liaoning, P.R. China. ¹⁴Department of Immunology and Infectious Diseases,

Harvard T.H. Chan School of Public Health, Boston, Massachusetts. ¹⁵Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts. ¹⁶Department of Epidemiology, Richard M. School of Public Health, Indianapolis, Indiana. ¹⁷Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana. ¹⁸Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts. ¹⁹Department of Medical Oncology, Yale Cancer Center, New Haven, Connecticut. ²⁰Department of Medicine, Yale School of Medicine, New Haven, Connecticut. ²¹Department of Medical Oncology, Smilow Cancer Hospital, New Haven, Connecticut.

Note: Supplementary data for this article are available at Cancer Prevention Research Online (<http://cancerprevres.aacrjournals.org/>).

W. Yang and L. Liu contributed equally as co-first authors for this article.

S. Ogino and X. Zhang contributed equally as co-last authors for this article.

Corresponding Authors: Xuehong Zhang, Brigham and Women's Hospital and Harvard Medical School, 181 Longwood Ave, Boston, MA 02115. Phone: 617-525-0342; Fax: 617-525-2008; E-mail: xuehong.zhang@channing.harvard.edu; and Shuji Ogino, sogino@bwh.harvard.edu

doi: 10.1158/1940-6207.CAPR-18-0279

©2019 American Association for Cancer Research.

Introduction

Research on calcium intake and colorectal neoplasia has important public health implications. Calcium is a simple, modifiable, inexpensive agent, and approximately 43% of U.S. adults use supplemental calcium (1). Furthermore, most epidemiologic studies (2–4) have reported an inverse association between higher calcium intake and risk of developing colorectal adenoma and cancer. However, evidence from the randomized controlled trials of calcium supplementation has been inconsistent (5, 6). Partly because of these discrepant findings, the Institute of Medicine called for more targeted research on calcium and colorectal cancer (7). Most previous studies have investigated total colorectal cancer, but this tumor comprises a group of heterogeneous subtypes (8), and the association with calcium intake may therefore differ by specific molecular subtypes (9). Hence, integrating host factors (such as diet) and tumor molecular features (such as immunity status) may enhance our understanding of the mechanisms through which calcium may act on colorectal carcinogenesis.

Accumulating evidence suggests that effector or cytotoxic ($CD3^+$ cells and $CD8^+$ cells), memory [$CD45RO$ ($PTPRC$) $^+$ cells], and regulatory ($FOXP3^+$ cells) T cells play an important role in colorectal cancer development and prognosis (10–12). Calcium acts as second messenger in lymphocytes that enhances T-cell proliferation and regulates its differentiation, and gene expression (13, 14). Hence, it is plausible that calcium may influence colorectal carcinogenesis through immunity. In fact, human trials showed that supplementation with calcium could reduce several tumor-promoting inflammation biomarkers (15–17), and reverse the upregulation of expression of genes involved in inflammation and immune response induced by Western-style diet which is low in calcium (18). In light of the biological evidence, we hypothesized that the association between calcium intake and colorectal cancer risk might differ by tumor immunity status defined by densities of infiltrated T cells in the tumor microenvironment.

To test this hypothesis, we conducted an immunologic molecular pathologic epidemiology study (8) by integrating data on calcium intake, colorectal cancer outcomes, and tumor pathologic immunity status from two large U.S. nationwide prospective cohorts, the Nurses' Health Study (NHS), and the Health Professionals Follow-up Study (HPFS). We examined the association between calcium intake and risk of colorectal cancer according to the T-cell densities in tumor tissue.

Materials and Methods

Study population

The study population included 121,700 female participants from NHS and 51,529 male participants from HPFS (19, 20). Briefly, for NHS, the recruitment of

121,700 U.S. female registered nurses ages 30–55 years was completed in 1976. For HPFS, the recruitment of 51,529 U.S. male professionals ages 40–75 years was completed in 1986. In both cohorts, questionnaires were administered biennially to collect and update information on demographic characteristics, lifestyle factors, and medical history, with follow-up rates over 90% in each cohort. This study was approved by the institutional review boards of the Brigham and Women's Hospital and Harvard T.H. Chan School of Public Health (Boston, MA). In this study, we excluded participants with a history of cancer (except for non-melanoma skin cancer), polyposis syndrome, ulcerative colitis/Crohn disease, implausible energy intakes at baseline (<600 or >3,500 kcal/day for women, or <800 or >4,200 kcal/day for men), or with no reports of calcium intake. After exclusion, a total of 136,249 participants (88,509 women and 47,740 men) were included in this analysis. A flow chart showing how the study population for analysis was developed is presented in Supplementary Fig. S1.

Assessments of calcium intake and other dietary factors

Details on assessments of calcium intake, as well as other dietary factors were described previously (2, 9, 21). In brief, we used validated (22, 23) semiquantitative food frequency questionnaires (FFQ) to collect dietary information at baseline and every 4 year thereafter. The energy-adjusted correlation coefficients of total calcium intake comparing the FFQs and the average of multiple 1-week diet records were 0.61 for men (22) and 0.63 for women (23). The correlation coefficients for dietary calcium intake were 0.60 for men (22) and 0.70 for women (23). We also collected information on dietary factors including intakes of alcohol, vitamin D, folate, red meat, and processed meat (22, 24).

Assessments of covariates

We collected information on potential colorectal cancer risk factors including height, adult body weight, physical activity [metabolic equivalent task score (METS)-hours/week], cigarette smoking, sigmoidoscopy/colonoscopy screening, family history of colorectal cancer, aspirin use, and menopausal status and use of menopausal hormones on the baseline and updated in biennial follow-up questionnaires.

Ascertainment of colorectal cancer cases

The incident colorectal cancer cases were defined as a primary tumor with International Classification of Diseases-9 codes of 153 and 154. Participants from the two cohorts were asked for written permission to obtain medical records and pathologic reports if they reported colorectal cancer on biennial questionnaires. We searched state vital statistics records, the National Death Index, to identify additional unreported cancer deaths. For all deaths attributable to colorectal cancer, we requested permission from next-of-kin to review medical records. All possible cancer

cases were further confirmed through review of medical and pathologic records. A study physician who was blinded to exposure data abstracted information on tumor anatomic location, stage, and histology type. We included colon and rectal carcinoma cases based on the colorectal continuum model (25, 26).

Tumor immunity and molecular analyses

We constructed tissue microarray (TMA; ref. 27), and assessed $CD3^+$ cell, $CD8^+$ cell, $CD45RO$ ($PTPRC$) $^+$ cell, and $FOXP3^+$ cell densities in tumor tissue using IHC. We used image analysis through an automated scanning microscope and the Ariol Image Analysis System (Genetix) to calculate the average density (cells/mm²) of each T-cell subset in TMA cores, as reported previously (10). We classified each of the T-cell densities (cells/mm²) into quartiles (Q1–Q4) and divided cases into two groups: low (Q1–Q2) or high (Q3–Q4) in the analyses for statistical efficiency. We also analyzed tumor microsatellite instability (MSI) status and calcium sensing receptor ($CASR$) expression as reported previously (9, 28, 29). DNA from paraffin-embedded tissue was extracted. The status of MSI was determined by analyzing variability in the length of the microsatellite markers from tumor DNA compared with normal DNA, including D2S123, D5S346, D17S250, BAT25, BAT26, BAT40, D18S55, D18S56, D18S67, and D18S487 (29). As described previously (9), we constructed TMAs from colorectal cancer blocks, and conducted IHC for $CASR$. $CASR$ expression levels in all cases were reviewed by Y. Masugi. For agreement study, selected tumors ($n = 118$) were independently examined by a second observer (Z.R. Qian), and the concordance between the two observers (Y. Masugi and Z.R. Qian) was reasonable with a weighted κ of 0.71 [95% confidence interval (CI), 0.61–0.82; ref. 9].

Statistical analysis

Age-adjusted and multivariable-adjusted cohort-specific HRs and 95% CIs for each colorectal cancer subtype according to the densities of tumor-infiltrated T-cell subsets (i.e., $CD3^+$ cells, $CD8^+$ cells, $CD45RO^+$ cells, and $FOXP3^+$ cells) were calculated using the duplication method Cox proportional hazards regression model (30). This method permits the estimation of separate regression coefficients for the exposure stratified by CRC subtype defined by the densities of tumor-infiltrated T-cell subsets (30). The model was stratified simultaneously by age (in months) and year of questionnaire return (every 2 year since baseline questionnaire), accounting for the finest possible control of confounding for age and secular trends. Person-years of follow-up were calculated from the date of baseline questionnaire return to the date of diagnosis of colorectal cancer, date of death, loss to follow-up, or the end of follow-up (June 1, 2012 for the NHS and January 31, 2012 for the HPFS), whichever came first. Cancer cases

without tumor immunity data were censored at diagnosis. We used the energy-adjusted (31) cumulative average intake of total calcium as reported on all available questionnaires up to the start of each 4-year follow-up interval as the main exposure (2), to minimize within-person variation and to better reflect long-term intake. Likewise, we used cumulative average for covariates and modeled them as time-varying variables when appropriate to allow for potential changes over follow-up periods. The adjusted covariates, as well as their categorizations in the multivariable models are shown in Tables 1 and 2 footnotes. We found no violation of proportional hazard assumption.

Our primary hypothesis testing was the heterogeneity test on the subtype-specific associations (statistical linear trends) of calcium intake with risk of colorectal cancer subtypes classified by densities of tumor-infiltrating T cells. Considering multiple hypothesis testing for our four primary hypotheses associated with four immunity variables (i.e., densities of $CD3^+$ cells, $CD8^+$ cells, $CD45RO^+$ cells, and $FOXP3^+$ cells), we adjusted α level to 0.01 ($\approx 0.05/4$) by Bonferroni correction. All other analyses including evaluations of individual HRs and evaluations of a statistical linear trend in a specific stratum represent secondary analyses. We examined the statistical significance of the differences in association according to cancer subtypes using the likelihood ratio test that compared the model fit that allowed separate associations by different tumor immunity status with the model fit that assumed a common effect (30). Trend tests were conducted using the median of each category of total calcium intake as a continuous variable. To maximize statistical power, we combined the results from the two cohorts because we did not observe any significant heterogeneity between sex ($P_{\text{heterogeneity}}$ for sex = 0.16).

In secondary analyses, we examined the associations between calcium intake and colorectal cancer risk according to the densities of tumor-infiltrated T cells by sex, tumor location, and source of calcium intake. We also explored time-lagged analysis (2) using 8-year time latency. To account for potential confounding by tumor MSI status, we further evaluated these associations jointly by tumor-infiltrated T cells and MSI status. Lastly, we assessed the associations stratified by tumor $CASR$ status because we speculated that $CASR$ may partially mediate the potential effect of calcium on colorectal cancer immunoprevention (9). All analyses were performed using the SAS software (SAS Institute, Version 9.2).

Use of standardized official symbols

We use HUGO-approved official symbols (or root symbols) for genes and gene products, including $CASR$, $CD3$, $CD8$, $FOXP3$, $IL6$, $IL23$, LTA , and $PTPRC$, all of which are described at www.genenames.org. The official symbols are italicized to differentiate from nonitalicized colloquial names that are used along with the official symbols. This

Table 1. Baseline characteristics of participants by frequency of total calcium intake in the NHS (1980) and HPFS (1986)

	Total calcium intake (mg/d)				
	<600	600-799	800-999	1,000-1,199	≥1,200
Women (NHS)					
Number	34,137	24,290	14,732	8,325	7,022
Age, years ^a	46.5 (7.0)	46.8 (7.2)	46.8 (7.3)	46.7 (7.4)	47.1 (7.4)
White, %	96.4	98.0	98.3	98.4	98.2
Body mass index, kg/m ²	24.0 (4.2)	24.0 (4.2)	24.1 (4.1)	24.2 (4.1)	24.4 (4.4)
Activity, METS-hours/week	12.5 (18.0)	14.2 (19.7)	15.2 (21.5)	15.3 (21.0)	16.2 (26.4)
Family history of colorectal cancer, %	7.9	7.8	7.9	7.9	7.7
Regular aspirin use (2 or more tablets/week), %	33.1	33.4	32.7	31.4	30.6
Past smoking, %	25.3	28.8	29.2	28.9	28.5
Current smoking, %	32.0	27.5	26.4	26.0	26.1
Multivitamin use, %	28.5	33.8	37.9	40.6	45.0
History of sigmoidoscopy/endoscopy, %	9.9	10.0	10.0	10.6	10.4
Postmenopausal status, %	45.0	44.0	44.2	43.9	44.8
Postmenopausal hormone use, %	18.3	18.5	18.8	19.3	19.2
Total energy intake, kcal/day	1,573 (513)	1,546 (484)	1,565 (518)	1,602 (481)	1,569 (497)
Dietary calcium intake, mg/day	457 (97)	691 (61)	883 (71)	1,078 (88)	1,376 (263)
Dairy calcium intake, mg/day	211 (94)	413 (97)	595 (113)	791 (132)	1,082 (287)
Supplemental calcium intake ^b , mg/day	358 (434)	372 (426)	382 (424)	392 (433)	402 (456)
Alcohol, g/day	7.8 (12.5)	6.2 (9.6)	5.5 (8.8)	4.8 (8.1)	3.9 (7.2)
Total folate intake, µg/day	311 (228)	365 (236)	399 (253)	417.2 (262)	503 (504)
Total vitamin D, IU/day	238 (227)	309 (238)	378 (252)	451 (268)	606 (489)
Red meat, servings/week	3.2 (2.3)	2.4 (1.8)	2.1 (1.7)	1.9 (1.5)	1.5 (1.4)
Processed meat, servings/week	1.3 (1.9)	1.2 (1.8)	1.0 (1.6)	0.9 (1.6)	0.7 (1.2)
Total fat, g/day	73.6 (14.3)	69.9 (12.6)	66.9 (12.8)	64.9 (12.8)	61.9 (13.6)
Total fiber, g/day	15.4 (5.6)	17.4 (6.2)	18.1 (6.9)	17.9 (6.9)	17.6 (7.4)
ω-3 polyunsaturated fatty acids, g/day	0.2 (0.1)	0.2 (0.2)	0.2 (0.2)	0.2 (0.2)	0.2 (0.2)
ω-6 polyunsaturated fatty acids, g/day	6.4 (2.5)	6.3 (2.4)	6.1 (2.4)	6.0 (2.4)	5.9 (2.6)
Men (HPFS)					
Number	10,817	13,820	9,049	5,328	8,726
Age, years ^a	54.0 (9.6)	53.9 (9.7)	54.5 (9.9)	54.6 (9.9)	55.8 (9.8)
White, %	93.3	95.8	96.7	97.0	97.3
Body mass index, kg/m ²	25.6 (3.4)	25.6 (3.3)	25.5 (3.2)	25.4 (3.3)	25.4 (3.3)
Activity, METS-hours/week	18.3 (27.3)	20.8 (28.5)	22.3 (31.7)	21.8 (31.5)	22.6 (30.5)
Family history of colorectal cancer, %	8.7	8.3	8.3	8.6	8.5
Regular aspirin use (2 or more tablets/week), %	26.9	28.9	30.1	31.0	31.3
Past smoking, %	43.5	42.9	40.9	40.5	39.6
Current smoking, %	12.4	9.7	8.2	8.9	8.1
Multivitamin use, %	50.6	57.5	62.0	67.3	74.2
History of sigmoidoscopy/endoscopy, %	24.0	26.2	26.9	26.7	27.1
Total energy intake, kcal/day	1,957 (638)	1,994 (605)	1,956 (632)	2,111 (631)	1,959 (583)
Dietary calcium intake, mg/day	500 (76)	683 (78)	845 (115)	982 (109)	1,180 (395)
Dairy calcium intake, mg/day	201 (76)	357 (98)	506 (136)	643 (206)	838 (409)
Supplemental calcium intake, mg/day	7 (22)	21 (55)	52 (103)	118 (180)	423 (550)
Alcohol, g/day	15.5 (19.3)	11.8 (14.9)	9.6 (13.3)	9.9 (14.2)	8.2 (12.1)
Total folate intake, µg/day	381 (210)	447 (227)	497 (251)	529 (287)	612 (363)
Total vitamin D, IU/day	272 (241)	338 (253)	407 (279)	488 (291)	637 (371)
Red meat, servings/week	2.2 (1.9)	1.9 (1.6)	1.6 (1.5)	1.7 (1.5)	1.4 (1.4)
Processed meat, servings/week	1.4 (2.0)	1.3 (1.8)	1.1 (1.8)	1.2 (1.9)	1.0 (1.7)
Total fat, g/day	73.5 (14.6)	72.2 (13.3)	70.2 (13.7)	70.6 (13.8)	68.6 (14.5)
Total fiber, g/day	19.1 (6.4)	21.1 (6.5)	22.3 (7.1)	21.6 (7.6)	21.8 (7.9)
ω-3 polyunsaturated fatty acids, g/day	0.3 (0.3)	0.3 (0.3)	0.3 (0.3)	0.3 (0.3)	0.3 (0.2)
ω-6 polyunsaturated fatty acids, g/day	12.2 (3.8)	12.0 (3.5)	11.6 (3.4)	11.5 (3.4)	10.9 (3.4)

NOTE: Values are means (SD) or percentages and are standardized to the age distribution of the study population.

^aValue is not age adjusted.

^bCalcium supplement data of NHS were based on questionnaires returned in 1986.

format enables readers to familiarize the official symbols for genes and gene products together with common colloquial names.

Results

During up to 32 years of follow-up of 136,249 participants (88,509 women and 47,740 men) in these prospec-

tive cohorts, we identified 3,079 colorectal adenocarcinoma cases. Among cases with available tissue specimens, we could assess T-cell infiltration in the tumor microenvironment for 736 cases (472 women and 264 men). The included colorectal cancer cases with immunity data were comparable to all eligible patients with colorectal cancer without immunity data (Supplementary Table S1). Participants with lower total calcium intake were more likely to

Table 2. Total calcium intake and risk of colorectal cancer according to densities of tumor-infiltrating T-cell subsets in the NHS (1980–2012) and HPFS (1986–2012)

	Total calcium intake (mg/d)					P_{trend}^a	$P_{\text{heterogeneity}}^b$
	<600	600–799	800–999	1,000–1,199	≥1200		
Total colorectal cancer							
Person-years ($n = 3,663,039$)	617,339	889,849	809,364	596,191	750,297		
No. cases ($n = 736$)	116	207	176	121	116		
Age-adjusted HR (95% CI)	1 (ref)	1.10 (0.87–1.38)	1.00 (0.79–1.27)	0.94 (0.72–1.21)	0.68 (0.53–0.89)	0.0002	
Multivariable HR (95% CI) ^c	1 (ref)	1.12 (0.89–1.42)	1.04 (0.80–1.34)	1.01 (0.76–1.34)	0.80 (0.60–1.08)	0.04	
CD3⁺							
Low							
No. cases ($n = 347$)	64	103	73	58	49		
Age-adjusted HR (95% CI)	1 (ref)	1.01 (0.74–1.39)	0.78 (0.56–1.10)	0.85 (0.59–1.22)	0.55 (0.38–0.80)	0.0004	0.34
Multivariable HR (95% CI) ^c	1 (ref)	1.02 (0.74–1.40)	0.80 (0.56–1.14)	0.89 (0.61–1.31)	0.63 (0.42–0.94)	0.01	0.30
High							
No. cases ($n = 350$)	48	98	91	56	57		
Age-adjusted HR (95% CI)	1 (ref)	1.22 (0.86–1.73)	1.20 (0.84–1.71)	1.00 (0.67–1.48)	0.76 (0.52–1.13)	0.03	
Multivariable HR (95% CI) ^c	1 (ref)	1.24 (0.88–1.77)	1.24 (0.86–1.78)	1.07 (0.71–1.61)	0.89 (0.58–1.35)	0.20	
CD8⁺							
Low							
No. cases ($n = 339$)	59	93	86	55	46		
Age-adjusted HR (95% CI)	1 (ref)	0.95 (0.68–1.32)	0.91 (0.65–1.27)	0.77 (0.53–1.11)	0.48 (0.33–0.72)	<0.0001	0.06
Multivariable HR (95% CI) [§]	1 (ref)	0.95 (0.68–1.33)	0.92 (0.65–1.30)	0.80 (0.54–1.18)	0.55 (0.36–0.84)	0.002	0.06
High							
No. cases ($n = 344$)	47	104	79	57	57		
Age-adjusted HR (95% CI)	1 (ref)	1.38 (0.97–1.95)	1.16 (0.80–1.67)	1.17 (0.79–1.74)	0.90 (0.60–1.33)	0.14	
Multivariable HR (95% CI) ^c	1 (ref)	1.40 (0.98–1.98)	1.18 (0.81–1.72)	1.24 (0.82–1.87)	1.02 (0.67–1.55)	0.47	
CD45RO⁺							
Low							
No. cases ($n = 348$)	65	98	80	57	48		
Age-adjusted HR (95% CI)	1 (ref)	0.91 (0.66–1.24)	0.81 (0.58–1.13)	0.79 (0.55–1.13)	0.50 (0.35–0.74)	0.0002	0.11
Multivariable HR (95% CI) ^c	1 (ref)	0.92 (0.67–1.27)	0.84 (0.59–1.18)	0.84 (0.57–1.23)	0.58 (0.39–0.87)	0.006	0.09
High							
No. cases ($n = 359$)	47	101	89	60	62		
Age-adjusted HR (95% CI)	1 (ref)	1.35 (0.96–1.92)	1.25 (0.87–1.79)	1.14 (0.77–1.68)	0.89 (0.61–1.31)	0.12	
Multivariable HR (95% CI) ^c	1 (ref)	1.38 (0.97–1.96)	1.29 (0.89–1.86)	1.22 (0.81–1.82)	1.04 (0.69–1.58)	0.54	
FOXP3⁺							
Low							
No. cases ($n = 336$)	61	89	89	55	42		
Age-adjusted HR (95% CI)	1 (ref)	0.91 (0.65–1.26)	0.98 (0.70–1.36)	0.81 (0.56–1.17)	0.47 (0.32–0.71)	0.0001	0.04
Multivariable HR (95% CI) ^c	1 (ref)	0.92 (0.66–1.29)	1.01 (0.72–1.43)	0.87 (0.59–1.28)	0.56 (0.36–0.85)	0.006	0.04
High							
No. cases ($n = 337$)	45	95	74	59	64		
Age-adjusted HR (95% CI)	1 (ref)	1.30 (0.91–1.85)	1.05 (0.72–1.53)	1.16 (0.78–1.72)	0.94 (0.64–1.39)	0.29	
Multivariable HR (95% CI) ^c	1 (ref)	1.32 (0.92–1.89)	1.07 (0.73–1.59)	1.23 (0.81–1.86)	1.10 (0.72–1.67)	0.87	

NOTE: Duplication-method Cox proportional cause-specific hazards regression for competing risks data was used to compute HRs and 95% CIs.

All analyses were stratified by age (in month), year of questionnaire return, and sex.

^aLinear trend test using the median intake of each category.

^bThe likelihood ratio test was used to test for the heterogeneity of the association between total calcium intake and colorectal cancer risk by densities of tumor-infiltrating T-cell subsets.

^cMultivariable HRs were adjusted for age (in month), race (Caucasian vs. non-Caucasian), adult body mass index (<25, 25–<27.5, 27.5–<30, or ≥30 kg/m²), smoking (0, 1–10, or >10 pack-years), history of colorectal cancer in a parent or sibling (yes or no), history of sigmoidoscopy/colonoscopy (yes or no), physical activity (<3, 3–<27, or ≥27 MET-hours/week), regular aspirin use (yes or no), alcohol consumption (0–<5, 5–<15, or ≥15 g/d), energy-adjusted total intake of folate, vitamin D, red meat, and processed meat (all in tertiles).

be current smokers, consumed more alcohol, and tended to have higher intake of red meat, processed meat, and fat, but less vitamin D and folate (Table 1).

As shown in Table 2, we found that higher calcium intake appeared to be associated with a lower risk of colorectal carcinomas containing low densities of CD8⁺ cells ($P_{\text{trend}} = 0.002$) but not with risk of carcinoma containing high densities of CD8⁺ cells ($P_{\text{trend}} = 0.47$), although the difference was not statistically significant ($P_{\text{heterogeneity}} = 0.06$, with the adjusted α of 0.01 by Bonferroni correction). Specifically, compared with calcium intake of <600 mg/day, calcium intake of ≥1,200 mg/day

was associated with a multivariable HR of 0.55 (95% CI, 0.36–0.84) for CD8⁺ T-cell–low tumors and of 1.02 (95% CI, 0.67–1.55) for CD8⁺ T-cell–high tumors. Similarly, the corresponding HRs (95% CIs) for low versus high T-cell tumors were 0.63 (0.42–0.94; $P_{\text{trend}} = 0.01$) and 0.89 (0.58–1.35; $P_{\text{trend}} = 0.20$) for CD3⁺ ($P_{\text{heterogeneity}} = 0.30$); 0.58 (0.39–0.87; $P_{\text{trend}} = 0.006$) and 1.04 (0.69–1.58; $P_{\text{trend}} = 0.54$) for CD45RO⁺ ($P_{\text{heterogeneity}} = 0.09$); and 0.56 (0.36–0.85; $P_{\text{trend}} = 0.006$) and 1.10 (0.72–1.67; $P_{\text{trend}} = 0.47$) for FOXP3⁺ ($P_{\text{heterogeneity}} = 0.04$), although the differences by subtypes defined by T-cell density were not statistically significant for any of the T cells examined.

Although statistical power was generally limited, the stronger inverse associations of calcium intake with tumors infiltrated with low densities of T cells but not high generally appeared consistent regardless of sex (Supplementary Tables S2 and S3), source of calcium intake (Table 3), tumor location (Supplementary Table S4), tumor MSI status (Supplementary Table S5), and time-lagged analyses (Supplementary Table S6). Interestingly, the potential differential associations appeared slightly stronger in *CASR*-positive tumors (Supplementary Table S7).

Discussion

In these two large prospective cohort studies, we found that higher calcium intake appeared to be primarily associated with lower risk of colorectal cancer infiltrated with low, but not high, densities of T cells regardless of the type of T cell examined, although the differences in the associations by subtype were not statistically significant for any of the T cells examined. These suggestive differential associations generally persisted regardless of sex, source of calcium intake, tumor location, and tumor MSI status. Our findings suggest a possible role of calcium in colorectal cancer immunoprevention (32) through modulation of T cells.

The role of immunity in cancer development and progression is becoming increasingly recognized (33–36). In this study, we investigated whether the potential anticancer effect of calcium on colorectal cancer differs by immune status in the tumor microenvironment. The observed differential associations by tumor immunity status suggest potential crosstalk between calcium intake and host immunity in affecting colorectal carcinogenesis. In the immune system, calcium is essential for diverse cellular functions including proliferation, differentiation, and effector function (37). Changes in the flux of calcium ions (Ca^{2+}) through Ca^{2+} channels in lymphocyte membranes play an important role in the regulation of T-cell function and immunity (13, 14, 38). Of note, dysregulated Ca^{2+} responses are critical for T-cell-mediated autoimmunity and inflammation including inflammatory bowel disease (38, 39), a risk factor for colorectal cancer (15). In line with experimental studies showing a potential effect of calcium on immunity, clinical trials have shown that supplementation with calcium reduces several tumor-promoting inflammation biomarkers (15–17). Furthermore, a recent human crossover trial (18) showed that consumption of a Western-style diet (characterized by low calcium and vitamin D) modestly upregulated genes (e.g., HLA class genes), which are involved in inflammation and immune response. In contrast, supplementation of calcium (but not vitamin D) to Western-style diet reversed these deleterious effects, and

upregulated genes in the anti-inflammatory interferon signaling and the *IL23* pathways (18).

It is also possible that calcium exerts its immunomodulatory effect partially via *CASR*. The *CASR*, a calcium-binding G protein-coupled receptor, is expressed in the entire intestinal epithelium and plays a key role in the preservation of gut microbiota and immune homeostasis (40–42). The *CASR* is also functionally expressed in human T lymphocytes (43). Evidence shows that intestinal epithelial *CASR* deficiency enhances permeability of the epithelial barrier, leading to the translocation and dissemination of luminal bacteria and activation of local and systemic innate and adaptive proinflammatory immune responses (44). In addition, calcium may promote T lymphocyte function through activation of *CASR* to secrete cytokines including *IL6* and *LTA* (TNF- β ; ref. 43), which may play important roles in immune defense, as well as systemic inflammatory response. Collectively, our data support that calcium exerts its immunomodulatory effect partially via *CASR*, as the differential associations we observed by immunity status appeared slightly stronger in *CASR*-positive tumors than in *CASR*-negative tumors (see Supplementary Table S7). However, the exact mechanisms underlying these differential associations remain unclear. We emphasize that our study remains hypothesis generating and requires confirmation from independent studies.

Our study also suggests a different role of host immunity in mediating the effect of calcium and vitamin D in colorectal cancer chemoprevention because we previously found that the inverse association for plasma 25(OH)D was stronger for risk of colorectal cancer subtypes with intense immune reactions (35). Consistently, the aforementioned human crossover trial found that supplementing the Western-style diet with $1,25(\text{OH})_2\text{D}_3$ upregulated genes involved in immune response and inflammation pathways, whereas calcium supplementation largely abrogated these changes (18).

Recent studies showed that MSI-high colorectal cancers were sensitive to immune checkpoint blockade (45, 46), indicating an important interplay between MSI status and immune cells. MSI-high tumors have frame shift mutations in coding sequences throughout the genome, which may elicit intense and more diverse immune responses and improve cancer survival (47, 48). In this study, however, the observed differential associations appeared to be independent of MSI status. This suggests that MSI status is not the sole determinant of tumor immune response because the levels of T-cell infiltrates overlap considerably between MSI-high and non-MSI-high tumors, although are, on average, higher in MSI-high cancers (10).

Our current study has several strengths, including prospective cohort design, high follow-up rates, validated colorectal cancer outcomes, and the use of repeated measures of calcium and other covariates during follow-up of

Table 3. Intake of dietary calcium, dairy calcium, and calcium supplement and risk of colorectal cancer according to densities of tumor-infiltrating T-cell subsets in the NHS (1980–2012) and HPFS (1986–2012)

	Dietary calcium intake (mg/d)				<i>P</i> _{trend} ^a	<i>P</i> _{heterogeneity} ^b
	<600	600–749	750–899	>900		
Total colorectal cancer						
Person-years (<i>n</i> = 3,663,039)	1,006,115	1,018,393	769,809	868,723		
No. cases (<i>n</i> = 736)	205	210	160	161		
Age-adjusted HR (95% CI)	1 (ref)	0.97 (0.80–1.17)	0.98 (0.79–1.20)	0.86 (0.69–1.05)	0.15	
Multivariable HR (95% CI) ^c	1 (ref)	1.00 (0.82–1.23)	1.04 (0.83–1.30)	0.96 (0.76–1.21)	0.74	
CD3⁺						
Low						
No. cases (<i>n</i> = 347)	110	97	62	78		
Age-adjusted HR (95% CI)	1 (ref)	0.84 (0.64–1.11)	0.74 (0.54–1.01)	0.80 (0.60–1.08)	0.12	0.78
Multivariable HR (95% CI) ^c	1 (ref)	0.87 (0.66–1.15)	0.77 (0.56–1.06)	0.88 (0.64–1.20)	0.36	0.74
High						
No. cases (<i>n</i> = 350)	90	102	87	71		
Age-adjusted HR (95% CI)	1 (ref)	1.05 (0.79–1.39)	1.16 (0.86–1.56)	0.82 (0.60–1.12)	0.25	
Multivariable HR (95% CI) ^c	1 (ref)	1.08 (0.81–1.45)	1.23 (0.90–1.67)	0.90 (0.65–1.26)	0.63	
CD8⁺						
Low						
No. cases (<i>n</i> = 339)	101	100	72	66		
Age-adjusted HR (95% CI)	1 (ref)	0.94 (0.71–1.25)	0.91 (0.67–1.23)	0.74 (0.54–1.01)	0.06	0.36
Multivariable HR (95% CI) ^c	1 (ref)	0.97 (0.73–1.28)	0.94 (0.69–1.29)	0.80 (0.58–1.12)	0.20	0.36
High						
No. cases (<i>n</i> = 344)	91	98	77	78		
Age-adjusted HR (95% CI)	1 (ref)	1.01 (0.76–1.35)	1.05 (0.77–1.43)	0.91 (0.67–1.24)	0.53	
Multivariable HR (95% CI) ^c	1 (ref)	1.04 (0.78–1.39)	1.10 (0.80–1.51)	0.99 (0.71–1.37)	0.93	
CD45RO⁺						
Low						
No. cases (<i>n</i> = 348)	106	94	66	82		
Age-adjusted HR (95% CI)	1 (ref)	0.82 (0.62–1.09)	0.77 (0.56–1.05)	0.81 (0.60–1.09)	0.18	0.62
Multivariable HR (95% CI) ^c	1 (ref)	0.85 (0.64–1.13)	0.82 (0.59–1.12)	0.90 (0.66–1.23)	0.52	0.57
High						
No. cases (<i>n</i> = 359)	93	108	83	75		
Age-adjusted HR (95% CI)	1 (ref)	1.11 (0.84–1.47)	1.13 (0.84–1.52)	0.91 (0.67–1.24)	0.51	
Multivariable HR (95% CI) ^c	1 (ref)	1.15 (0.87–1.53)	1.20 (0.88–1.64)	1.03 (0.74–1.42)	0.91	
FOXP3⁺						
Low						
No. cases (<i>n</i> = 336)	104	89	62	81		
Age-adjusted HR (95% CI)	1 (ref)	0.81 (0.61–1.08)	0.75 (0.55–1.04)	0.84 (0.62–1.12)	0.22	0.57
Multivariable HR (95% CI) ^c	1 (ref)	0.85 (0.64–1.14)	0.81 (0.59–1.12)	0.94 (0.68–1.28)	0.64	0.59
High						
No. cases (<i>n</i> = 337)	82	102	85	68		
Age-adjusted HR (95% CI)	1 (ref)	1.18 (0.88–1.58)	1.30 (0.95–1.76)	0.93 (0.67–1.28)	0.68	
Multivariable HR (95% CI) ^c	1 (ref)	1.23 (0.91–1.65)	1.38 (1.01–1.90)	1.03 (0.73–1.45)	0.82	
Dairy calcium intake (mg/d)						
	0–299	300–499	500–699	>700		
Total colorectal cancer						
Person-years (<i>n</i> = 3,663,039)	1,045,066	1,372,061	749,951	495,962		
Cases, no. (<i>n</i> = 736)	223	266	149	98		
Age-adjusted HR (95% CI)	1 (ref)	0.90 (0.75–1.07)	0.90 (0.73–1.11)	0.87 (0.69–1.11)	0.25	
Multivariable HR (95% CI) ^c	1 (ref)	0.92 (0.76–1.10)	0.95 (0.76–1.19)	0.97 (0.75–1.26)	0.83	
CD3⁺						
Low						
No. cases (<i>n</i> = 347)	111	126	64	46		
Age-adjusted HR (95% CI)	1 (ref)	0.87 (0.67–1.12)	0.80 (0.59–1.09)	0.84 (0.59–1.19)	0.24	0.99
Multivariable HR (95% CI) ^c	1 (ref)	0.88 (0.68–1.14)	0.84 (0.61–1.15)	0.92 (0.64–1.32)	0.52	0.98
High						
No. cases (<i>n</i> = 350)	107	124	76	43		
Age-adjusted HR (95% CI)	1 (ref)	0.86 (0.66–1.11)	0.93 (0.70–1.26)	0.78 (0.55–1.11)	0.24	
Multivariable HR (95% CI) ^c	1 (ref)	0.88 (0.68–1.14)	0.98 (0.72–1.33)	0.86 (0.59–1.25)	0.54	
CD8⁺						
Low						
No. cases (<i>n</i> = 339)	100	131	71	37		
Age-adjusted HR (95% CI)	1 (ref)	0.99 (0.76–1.28)	0.95 (0.70–1.29)	0.76 (0.52–1.10)	0.17	0.61
Multivariable HR (95% CI) ^c	1 (ref)	1.00 (0.77–1.30)	0.99 (0.72–1.36)	0.82 (0.55–1.23)	0.40	0.62
High						
No. cases (<i>n</i> = 344)	109	118	66	51		
Age-adjusted HR (95% CI)	1 (ref)	0.81 (0.62–1.05)	0.82 (0.60–1.12)	0.91 (0.65–1.28)	0.50	
Multivariable HR (95% CI) ^c	1 (ref)	0.83 (0.63–1.08)	0.85 (0.62–1.17)	1.00 (0.70–1.42)	0.84	

(Continued on the following page)

Downloaded from <http://aacrjournals.org/cancerpreventionresearch/article-pdf/12/5/289/224294/289.pdf> by guest on 13 July 2024

Table 3. Intake of dietary calcium, dairy calcium, and calcium supplement and risk of colorectal cancer according to densities of tumor-infiltrating T-cell subsets in the NHS (1980–2012) and HPFS (1986–2012) (Cont'd)

	Dairy calcium intake (mg/d)					
	0–299	300–499	500–699	>700		
CD45RO⁺						
Low						
No. cases (n = 348)	113	119	67	49		
Age-adjusted HR (95% CI)	1 (ref)	0.81 (0.62–1.05)	0.81 (0.60–1.10)	0.86 (0.61–1.21)	0.35	0.80
Multivariable HR (95% CI) ^c	1 (ref)	0.82 (0.63–1.07)	0.85 (0.62–1.16)	0.95 (0.66–1.35)	0.71	0.72
High						
No. cases (n = 359)	104	132	77	46		
Age-adjusted HR (95% CI)	1 (ref)	0.93 (0.72–1.21)	0.99 (0.74–1.33)	0.88 (0.62–1.25)	0.56	
Multivariable HR (95% CI) ^c	1 (ref)	0.96 (0.74–1.25)	1.05 (0.77–1.43)	0.99 (0.69–1.44)	0.92	
FOXP3⁺						
Low						
No. cases (n = 336)	114	114	66	42		
Age-adjusted HR (95% CI)	1 (ref)	0.75 (0.58–0.98)	0.78 (0.58–1.06)	0.72 (0.50–1.02)	0.06	0.05
Multivariable HR (95% CI) ^c	1 (ref)	0.77 (0.59–1.01)	0.83 (0.61–1.14)	0.79 (0.54–1.15)	0.21	0.05
High						
No. cases (n = 337)	85	130	74	48		
Age-adjusted HR (95% CI)	1 (ref)	1.15 (0.87–1.51)	1.17 (0.85–1.60)	1.15 (0.80–1.64)	0.41	
Multivariable HR (95% CI) ^c	1 (ref)	1.18 (0.89–1.55)	1.22 (0.88–1.69)	1.27 (0.88–1.86)	0.19	
Calcium supplement (mg/d)						
	0–199	200–299	300–499	>500		
Total colorectal cancer						
Person-years (n = 3,663,039)	2,505,441	321,408	428,893	407,297		
No. cases (n = 736)	514	80	91	51		
Age-adjusted HR (95% CI)	1 (ref)	1.14 (0.89–1.45)	0.99 (0.78–1.25)	0.56 (0.42–0.75)	0.001	
Multivariable HR (95% CI) ^c	1 (ref)	1.22 (0.95–1.56)	1.10 (0.87–1.39)	0.67 (0.49–0.90)	0.09	
CD3⁺						
Low						
No. cases (n = 347)	251	32	41	23		
Age-adjusted HR (95% CI)	1 (ref)	0.93 (0.64–1.36)	0.93 (0.66–1.30)	0.52 (0.34–0.80)	0.006	0.52
Multivariable HR (95% CI) ^c	1 (ref)	0.99 (0.68–1.45)	1.03 (0.73–1.46)	0.62 (0.40–0.96)	0.07	0.49
High						
No. cases (n = 350)	237	43	48	22		
Age-adjusted HR (95% CI)	1 (ref)	1.32 (0.94–1.84)	1.12 (0.81–1.55)	0.51 (0.33–0.80)	0.05	
Multivariable HR (95% CI) ^c	1 (ref)	1.43 (1.02–2.00)	1.25 (0.90–1.74)	0.62 (0.39–0.97)	0.37	
CD8⁺						
Low						
No. cases (n = 339)	233	39	47	20		
Age-adjusted HR (95% CI)	1 (ref)	1.09 (0.77–1.54)	0.99 (0.72–1.37)	0.43 (0.27–0.68)	0.003	0.39
Multivariable HR (95% CI) ^c	1 (ref)	1.16 (0.82–1.65)	1.10 (0.79–1.53)	0.51 (0.32–0.81)	0.05	0.38
High						
No. cases (n = 344)	244	37	39	24		
Age-adjusted HR (95% CI)	1 (ref)	1.21 (0.85–1.72)	0.99 (0.70–1.41)	0.61 (0.40–0.94)	0.07	
Multivariable HR (95% CI) ^c	1 (ref)	1.30 (0.91–1.86)	1.10 (0.77–1.57)	0.73 (0.47–1.13)	0.42	
CD45RO⁺						
Low						
No. cases (n = 348)	258	34	37	19		
Age-adjusted HR (95% CI)	1 (ref)	1.01 (0.70–1.46)	0.85 (0.60–1.22)	0.43 (0.27–0.69)	0.0008	0.12
Multivariable HR (95% CI) ^c	1 (ref)	1.08 (0.75–1.56)	0.94 (0.65–1.34)	0.51 (0.31–0.82)	0.01	0.11
High						
No. cases (n = 359)	237	44	49	29		
Age-adjusted HR (95% CI)	1 (ref)	1.27 (0.92–1.78)	1.07 (0.78–1.48)	0.65 (0.44–0.97)	0.15	
Multivariable HR (95% CI) ^c	1 (ref)	1.36 (0.97–1.90)	1.19 (0.86–1.65)	0.77 (0.52–1.16)	0.67	
FOXP3⁺						
Low						
No. cases (n = 336)	238	35	41	22		
Age-adjusted HR (95% CI)	1 (ref)	1.09 (0.76–1.57)	0.96 (0.68–1.36)	0.53 (0.34–0.82)	0.01	0.63
Multivariable HR (95% CI) ^c	1 (ref)	1.18 (0.82–1.70)	1.08 (0.76–1.53)	0.63 (0.40–1.00)	0.15	0.64
High						
No. cases (n = 337)	226	44	42	25		
Age-adjusted HR (95% CI)	1 (ref)	1.35 (0.97–1.88)	0.99 (0.70–1.39)	0.59 (0.39–0.90)	0.06	
Multivariable HR (95% CI) ^c	1 (ref)	1.44 (1.03–2.02)	1.10 (0.78–1.55)	0.71 (0.46–1.09)	0.41	

NOTE: Duplication-method Cox proportional cause-specific hazards regression for competing risks data was used to compute HRs and 95% CIs.

All analyses were stratified by age (in month), year of questionnaire return and sex.

^aLinear trend test using the median intake of each category.

^bThe likelihood ratio test was used to test for the heterogeneity of the association between total calcium intake and colorectal cancer risk by densities of tumor-infiltrating T-cell subsets.

^cMultivariable HRs were adjusted for age (in month), race (Caucasian vs. non-Caucasian), adult body mass index (<25, 25–<27.5, 27.5–<30, or ≥30 kg/m²), smoking (0, 1–10, or >10 pack-years), history of colorectal cancer in a parent or sibling (yes or no), history of sigmoidoscopy/colonoscopy (yes or no), physical activity (<3, 3–<27, or ≥27 MET-hours/week), regular aspirin use (yes or no), alcohol consumption (0–<5, 5–<15, or ≥15 g/d), energy-adjusted total intake of folate, vitamin D, red meat, and processed meat (all in tertiles).

the cohorts. The integration of tumor immunology analyses into the framework of molecular pathologic epidemiology is an emerging research area (49, 50), which enabled us to better understand etiologic heterogeneity according to tumor molecular and immune features. However, several limitations should be noted. First, despite the overall large sample size of the cohorts, we had a limited number of cases with tumor tissue data on T-cell infiltration for the secondary analyses by anatomic subsites, sources of calcium intake, tumor MSI, or CASR status. Second, the inclusion of cancer cases with available tissue specimen may introduce potential selection bias. However, cases that provided tumor tissue were comparable with all eligible cases with regard to a number of demographic, dietary, and lifestyle factors. Third, because most of participants in our study are Caucasian U.S. health professionals, the generalizability of our findings to the general population is limited. However, little heterogeneity across diverse populations has been suggested in the association between calcium intake and risks of colorectal cancer (3). Lastly, we cannot rule out residual confounding although we have adjusted for a wide range of known risk factors for colorectal cancer.

In summary, we found inverse associations between calcium intake and risk of colorectal cancers with low densities of T-cell infiltration, but not with risk of colorectal cancers with high densities of T-cell infiltration, although the differences by subtypes defined by T-cell density were not statistically significant for any of the T cells examined. Our results suggest a possible immunomodulatory effect of calcium in colorectal carcinogenesis. Future studies are warranted to confirm our findings and elucidate the underlying mechanisms for colorectal cancer immunoprevention by calcium.

Disclosure of Potential Conflicts of Interest

K. Ng reports receiving commercial research grant from Pharmavite, Genentech, Tarrex Biopharma, and Gilead and is a consultant/advisory board member for Bayer, Seattle Genetics, and Tarrex. W.S. Garrett reports receiving speakers bureau honoraria from Merck, Janssen, and Pfizer and is a consultant/advisory board member for BiomX, Kintai Therapeutics, and Evelo Biosciences. M. Giannakis is a consultant/advisory board member for AstraZeneca. C.S. Fuchs is a consultant/advisory board member for Merck, Entrinsic Health, CytomX, Taiho Pharmaceutical, Sanofi, Eli Lilly, and Unum Therapeutics. No potential conflicts of interest were disclosed by the other authors.

Disclaimer

The funders had no role in design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. The authors assume full responsibility for analyses and interpretation of these data. The content is solely the responsibility of the authors and does not necessarily represent the official views of NIH. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Authors' Contributions

Conception and design: W. Yang, L. Liu, N. Keum, A.T. Chan, C.S. Fuchs, E.L. Giovannucci, S. Ogino, X. Zhang

Development of methodology: Z.R. Qian, M. Song, S. Ogino, X. Zhang

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): L. Liu, Z.R. Qian, T. Hamada, K. Noshio, Y. Masugi, K. Kosumi, M. Giannakis, A.T. Chan, C.S. Fuchs, S. Ogino, X. Zhang

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): W. Yang, L. Liu, N. Keum, Z.R. Qian, M. Song, Y. Cao, S.A. Smith-Warner, S. Zhang, K. Ng, K. Kosumi, Y. Ma, W.S. Garrett, J.A. Meyerhardt, E.L. Giovannucci, S. Ogino, X. Zhang

Writing, review, and/or revision of the manuscript: W. Yang, L. Liu, N. Keum, Z.R. Qian, J.A. Nowak, T. Hamada, M. Song, S.A. Smith-Warner, S. Zhang, Y. Masugi, K. Ng, Y. Ma, W.S. Garrett, M. Wang, H. Nan, J.A. Meyerhardt, A.T. Chan, C.S. Fuchs, K. Wu, E.L. Giovannucci, S. Ogino, X. Zhang

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): L. Liu, Z.R. Qian, Y. Masugi, A.T. Chan

Study supervision: J.A. Nowak, A.T. Chan, C.S. Fuchs, R. Nishihara, S. Ogino, X. Zhang

Acknowledgments

We would like to thank the participants and staff of the Nurses' Health Study and Health Professionals Follow-up Study for their valuable contributions as well as the following state cancer registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, WY. This work was supported by the NIH (P01 CA87969 and UM1 CA186107, to M.J. Stampfer; P01 CA55075 and UM1 CA167552 to W.C. Willett; U01 CA167552 to W.C. Willett and L.A. Mucci; P50 CA127003, R01 CA118553, R01 CA169141, R01 CA137178, and K24 DK098311 to A.T. Chan; R01 CA205406 to K. Ng.; R01 CA151993 and R35 CA197735 to S. Ogino; K07 CA190673 to R. Nishihara; and R03 CA176717 and K07 CA188126 to X. Zhang); Nodal Award (to S. Ogino) from the Dana-Farber Harvard Cancer Center; Research supported by a Stand Up To Cancer Colorectal Cancer Dream Team Translational Research Grant (grant no.: SU2C-AACR-DT22-17) to C.S. Fuchs Stand Up To Cancer is a division of the Entertainment Industry Foundation. Research grants are administered by the American Association for Cancer Research, the Scientific Partner of SU2C; and by grants from The Project P Fund for Colorectal Cancer Research, The Friends of the Dana-Farber Cancer Institute, Bennett Family Fund, and the Entertainment Industry Foundation through National Colorectal Cancer Research Alliance. W. Yang and L. Liu were supported by scholarship grants from Chinese Scholarship Council. L. Liu was also supported by a fellowship grant from Huazhong University of Science and Technology. K. Kosumi was supported by the JSPS Overseas Research Fellowships grant from the Japan Society for the Promotion of Science (JP2017-775).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received July 21, 2018; revised September 27, 2018; accepted February 4, 2019; published first February 13, 2019.

References

- Bailey RL, Dodd KW, Goldman JA, Gahche JJ, Dwyer JT, Moshfegh AJ, et al. Estimation of total usual calcium and vitamin D intakes in the United States. *J Nutr* 2010;140:817–22.
- Zhang X, Keum N, Wu K, Smith-Warner SA, Ogino S, Chan AT, et al. Calcium intake and colorectal cancer risk: Results from the nurses' health study and health professionals follow-up study. *Int J Cancer* 2016;139:2232–42.
- Keum N, Aune D, Greenwood DC, Ju W, Giovannucci EL. Calcium intake and colorectal cancer risk: dose-response meta-analysis of prospective observational studies. *Int J Cancer* 2014;135:1940–8.
- World Cancer Research Fund/American Institute for Cancer Research. Continuous update project report summary. Food, Nutrition, Physical Activity, and the Prevention of Colorectal Cancer; 2011. Available from: <https://www.wcrf.org/sites/default/files/Colorectal-Cancer-2011-Report.pdf>.
- Wactawski-Wende J, Kotchen JM, Anderson GL, Assaf AR, Brunner RL, O'Sullivan MJ, et al. Calcium plus vitamin D supplementation and the risk of colorectal cancer. *N Engl J Med* 2006;354:684–96.
- Baron JA, Barry EL, Mott LA, Rees JR, Sandler RS, Snover DC, et al. A trial of calcium and vitamin D for the prevention of colorectal adenomas. *N Engl J Med* 2015;373:1519–30.
- Institute of Medicine (US) Committee to Review Dietary Reference Intakes for Vitamin D and Calcium. Ross AC, Taylor CL, Yaktine AL, Del Valle HB, editors. Dietary reference intakes for calcium and vitamin D, Washington (DC): National Academies Press; 2011.
- Ogino S, Chan AT, Fuchs CS, Giovannucci E. Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. *Gut* 2011;60:397–411.
- Yang W, Liu L, Masugi Y, Qian ZR, Nishihara R, Keum N, et al. Calcium intake and risk of colorectal cancer according to expression status of calcium-sensing receptor (CASR). *Gut* 2018;67:1475–83.
- Nosho K, Baba Y, Tanaka N, Shima K, Hayashi M, Meyerhardt JA, et al. Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. *J Pathol* 2010;222:350–66.
- Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D, et al. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. *J Clin Oncol* 2009;27:186–92.
- Ohtani H. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human colorectal cancer. *Cancer Immun* 2007;7:4.
- Feske S, Skolnik EY, Prakriya M. Ion channels and transporters in lymphocyte function and immunity. *Nat Rev Immunol* 2012;12:532–47.
- Monteith GR, Prevarskaya N, Roberts-Thomson SJ. The calcium-cancer signalling nexus. *Nat Rev Cancer* 2017;17:367–80.
- Bostick RM. Effects of supplemental vitamin D and calcium on normal colon tissue and circulating biomarkers of risk for colorectal neoplasms. *J Steroid Biochem Mol Biol* 2015;148:86–95.
- Fedirko V, Bostick RM, Long Q, Flanders WD, McCullough ML, Sidelnikov E, et al. Effects of supplemental vitamin D and calcium on oxidative DNA damage marker in normal colorectal mucosa: a randomized clinical trial. *Cancer Epidemiol Biomarkers Prev* 2010;19:280–91.
- Hopkins MH, Owen J, Ahearn T, Fedirko V, Flanders WD, Jones DP, et al. Effects of supplemental vitamin D and calcium on biomarkers of inflammation in colorectal adenoma patients: a randomized, controlled clinical trial. *Cancer Prev Res* 2011;4:1645–54.
- Protiva P, Pendyala S, Nelson C, Augenlicht LH, Lipkin M, Holt PR. Calcium and 1,25-dihydroxyvitamin D3 modulate genes of immune and inflammatory pathways in the human colon: a human crossover trial. *Am J Clin Nutr* 2016;103:1224–31.
- Colditz GA, Hankinson SE. The Nurses' Health Study: lifestyle and health among women. *Nat Rev Cancer* 2005;5:388–96.
- Giovannucci E, Ascherio A, Rimm EB, Colditz GA, Stampfer MJ, Willett WC. Physical activity, obesity, and risk for colon cancer and adenoma in men. *Ann Intern Med* 1995;122:327–34.
- Wu K, Willett WC, Fuchs CS, Colditz GA, Giovannucci EL. Calcium intake and risk of colon cancer in women and men. *J Natl Cancer Inst* 2002;94:437–46.
- Rimm EB, Giovannucci EL, Stampfer MJ, Colditz GA, Litin LB, Willett WC. Reproducibility and validity of an expanded self-administered semiquantitative food frequency questionnaire among male health professionals. *Am J Epidemiol* 1992;135:1114–26.
- Willett WC, Sampson L, Stampfer MJ, Rosner B, Bain C, Witschi J, et al. Reproducibility and validity of a semiquantitative food frequency questionnaire. *Am J Epidemiol* 1985;122:51–65.
- Feskanich D, Rimm EB, Giovannucci EL, Colditz GA, Stampfer MJ, Litin LB, et al. Reproducibility and validity of food intake measurements from a semiquantitative food frequency questionnaire. *J Am Diet Assoc* 1993;93:790–6.
- Yamauchi M, Morikawa T, Kuchiba A, Imamura Y, Qian ZR, Nishihara R, et al. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. *Gut* 2012;61:847–54.
- Yamauchi M, Lochhead P, Morikawa T, Huttenhower C, Chan AT, Giovannucci E, et al. Colorectal cancer: a tale of two sides or a continuum? *Gut* 2012;61:794–7.
- Sherman ME, Howatt W, Blows FM, Pharoah P, Hewitt SM, Garcia-Closas M. Molecular pathology in epidemiologic studies: a primer on key considerations. *Cancer Epidemiol Biomarkers Prev* 2010;19:966–72.
- Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. *N Engl J Med* 2007;356:2131–42.
- Ogino S, Brahmandam M, Cantor M, Namgyal C, Kawasaki T, Kirkner G, et al. Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component. *Mod Pathol* 2006;19:59–68.
- Wang M, Spiegelman D, Kuchiba A, Lochhead P, Kim S, Chan AT, et al. Statistical methods for studying disease subtype heterogeneity. *Stat Med* 2016;35:782–800.
- Willett WC, Howe GR, Kushi LH. Adjustment for total energy intake in epidemiologic studies. *Am J Clin Nutr* 1997;65:1220S–8S.
- Kensler TW, Spira A, Garber JE, Szabo E, Lee JJ, Dong Z, et al. Transforming cancer prevention through precision medicine and immune-oncology. *Cancer Prev Res* 2016;9:2–10.
- Zitvogel L, Pietrocola F, Kroemer G. Nutrition, inflammation and cancer. *Nat Immunol* 2017;18:843–50.
- Basile D, Garattini SK, Bonotto M, Ongaro E, Casagrande M, Cattaneo M, et al. Immunotherapy for colorectal cancer: where are we heading? *Expert Opin Biol Ther* 2017;17:709–21.
- Song M, Nishihara R, Wang M, Chan AT, Qian ZR, Inamura K, et al. Plasma 25-hydroxyvitamin D and colorectal cancer risk according to tumour immunity status. *Gut* 2016;65:296–304.

36. Cao Y, Nishihara R, Qian ZR, Song M, Mima K, Inamura K, et al. Regular aspirin use associates with lower risk of colorectal cancers with low numbers of tumor-infiltrating lymphocytes. *Gastroenterology* 2016;151:879–92.
37. Oh-hora M, Rao A. Calcium signaling in lymphocytes. *Curr Opin Immunol* 2008;20:250–8.
38. Feske S. Calcium signalling in lymphocyte activation and disease. *Nat Rev Immunol* 2007;7:690–702.
39. McCarl CA, Khalil S, Ma J, Oh-hora M, Yamashita M, Roether J, et al. Store-operated Ca²⁺ entry through ORAI1 is critical for T cell-mediated autoimmunity and allograft rejection. *J Immunol* 2010;185:5845–58.
40. Owen JL, Cheng SX, Ge Y, Sahay B, Mohamadzadeh M. The role of the calcium-sensing receptor in gastrointestinal inflammation. *Semin Cell Dev Biol* 2016;49:44–51.
41. Jouret F, Wu J, Hull M, Rajendran V, Mayr B, Schofl C, et al. Activation of the Ca²⁺-sensing receptor induces deposition of tight junction components to the epithelial cell plasma membrane. *J Cell Sci* 2013;126:5132–42.
42. MacLeod RJ. Extracellular calcium-sensing receptor/PTH knockout mice colons have increased Wnt/beta-catenin signaling, reduced non-canonical Wnt signaling, and increased susceptibility to azoxymethane-induced aberrant crypt foci. *Lab Invest* 2013;93:520–7.
43. Li T, Sun M, Yin X, Wu C, Wu Q, Feng S, et al. Expression of the calcium sensing receptor in human peripheral blood T lymphocyte and its contribution to cytokine secretion through MAPKs or NF-kappaB pathways. *Mol Immunol* 2013;53:414–20.
44. Cheng SX, Lightfoot YL, Yang T, Zadeh M, Tang L, Sahay B, et al. Epithelial CaSR deficiency alters intestinal integrity and promotes proinflammatory immune responses. *FEBS Lett* 2014;588:4158–66.
45. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. *N Engl J Med* 2015;372:2509–20.
46. Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. *Science* 2017;357:409–13.
47. Mlecnik B, Bindea G, Angell HK, Maby P, Angelova M, Tougeron D, et al. Integrative analyses of colorectal cancer show immunoscore is a stronger predictor of patient survival than microsatellite instability. *Immunity* 2016;44:698–711.
48. Rozek LS, Schmit SL, Greenson JK, Tomsho LP, Rennert HS, Rennert G, et al. Tumor-infiltrating lymphocytes, Crohn's-like lymphoid reaction, and survival from colorectal cancer. *J Natl Cancer Inst* 2016;108:djw027.
49. Ogino S, Nowak JA, Hamada T, Phipps AI, Milner DA Jr, et al. Integrative analysis of exogenous, endogenous, tumour and immune factors for precision medicine. *Gut* 2018;67:1168–80.
50. Ogino S, Nowak JA, Hamada T, Milner DA Jr, Nishihara R. Insights into pathogenic interactions among environment, host, and tumor at the crossroads of molecular pathology and epidemiology. *Annu Rev Pathol* 2019;14:83–103.

